1. Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
- Author
-
Zinsz A, Ahrari S, Becker J, Mortada A, Roch V, Doriat L, Santi M, Blonski M, Taillandier L, Zaragori T, and Verger A
- Subjects
- Humans, Female, Male, Middle Aged, Prognosis, Aged, Amino Acids, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Retrospective Studies, Neoplasm Grading, Dihydroxyphenylalanine analogs & derivatives, Follow-Up Studies, Temozolomide therapeutic use, Glioma drug therapy, Glioma diagnostic imaging, Positron-Emission Tomography methods, Brain Neoplasms diagnostic imaging, Brain Neoplasms drug therapy, Brain Neoplasms metabolism, Brain Neoplasms pathology, Antineoplastic Agents, Alkylating therapeutic use
- Abstract
Purpose: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol., Methods: The analysis included consecutive HGG patients with dynamic [18F]FDOPA PET imaging within 3 months of the end of TMZ therapy, post-Stupp protocol. Static and dynamic PET parameters, responses to RANO criteria for MRI and clinical and histo-molecular factors were correlated to progression-free (PFS)., Results: Thirty-two patients (59.4 [54.0;67.6] years old, 13 (41%) women) were included. Static PET parameters peak tumor-to-background ratio and metabolic tumor volume (respective thresholds of 1.9 and 1.5 mL) showed the best 84% accuracies for predicting PFS at 6 months (p = 0.02). These static PET parameters were also independent predictor of PFS in multivariate analysis (p ≤ 0.05)., Conclusion: In HGG patients having undergone a Stupp protocol, the absence of significant PET uptake after TMZ constitutes a favorable prognostic factor., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF